Chronic Myeloid Leukemia /Features

TIDEL II trial: uncovering the predictive value of ABCB1 in determining the long-term response to imatinib in CML patients

Adelaide researchers based at the South Australian Health and Medical Research Institute (SAHMRI) have demonstrated the significance of early increases…

Chronic Myeloid Leukemia
2 years
The content of VJHemOnc is intended for healthcare professionals